An Analysis of Avidity Biosciences Inc (RNA)’s Potential Price Growth

NUE

In a filing, Avidity Biosciences Inc revealed its Chief Scientific Officer Flanagan W. Michael unloaded Company’s shares for reported $0.66 million on Jun 11 ’25. In the deal valued at $32.88 per share,20,000 shares were sold. As a result of this transaction, Flanagan W. Michael now holds 80,195 shares worth roughly $2.39 million.

Then, WILLIAM MICHAEL FLANAGAN bought 20,000 shares, generating $672,400 in total proceeds.

Before that, Gallagher Kathleen P. sold 5,875 shares. Avidity Biosciences Inc shares valued at $190,833 were divested by the Chief Program Officer at a price of $32.48 per share. As a result of the transaction, Gallagher Kathleen P. now holds 50,554 shares, worth roughly $1.51 million.

Raymond James initiated its Avidity Biosciences Inc [RNA] rating to a Strong buy in a research note published on June 11, 2025; the price target was $65. A number of analysts have revised their coverage, including Citigroup’s analysts, who began to cover the stock in mid March with a ‘”a Buy”‘ rating. BMO Capital Markets began covering RNA with “an Outperform” recommendation on March 12, 2025. Scotiabank started covering the stock on March 07, 2025. It rated RNA as “a Sector outperform”.

Price Performance Review of RNA

On Monday, Avidity Biosciences Inc [NASDAQ:RNA] saw its stock fall -5.00% to $29.80. Over the last five days, the stock has lost -8.76%. Avidity Biosciences Inc shares have risen nearly 2.48% since the year began. Nevertheless, the stocks have fallen -22.31% over the past one year. While a 52-week high of $56.00 was reached on 06/09/25, a 52-week low of $21.51 was recorded on 04/09/25.

Levels Of Support And Resistance For RNA Stock

The 24-hour chart illustrates a support level at 29.16, which if violated will result in even more drops to 28.52. On the upside, there is a resistance level at 31.05. A further resistance level may holdings at 32.29.

The most recent change occurred on December 20, 2024 when H.C. Wainwright began covering the stock and recommended ‘”a Buy”‘ rating along with a $72 price target.

Most Popular

Knox Daily
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.